2024 Moderna earnings - Feb 16, 2023 · For the last reported quarter, it was expected that Moderna would post earnings of $3.04 per share when it actually produced earnings of $2.53, delivering a surprise of -16.78%.

 
Moderna, Inc. ( MRNA) reported Q1 FY 2022 earnings that far surpassed analyst expectations. Earnings per share (EPS) came in positive for the fifth straight …. Moderna earnings

MRNA | Complete Moderna Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Moderna posted net income of $79 million, or 19 cents per share, for the quarter. That's compared with $3.66 billion in net income, or $8.58 per share, reported …Moderna is slated to release its fourth-quarter earnings on February 24. Analysts expect the Massachusetts-based firm will report $6.8 billion in revenue, up 1,090% from one year prior. Key BackgroundModerna's vaccine for adults ages 60 and older could hit the market a year behind shots from Pfizer and GSK . Moderna ... But earnings plunged 29% to $20.12 per share.October 26, 2023 at 7:02 AM · 5 min read. The market expects Moderna (MRNA) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended ...AP Fellow. Moderna earned $12.2 billion in profit in 2021, with the majority of this total coming from its vaccine production. The sales of the Moderna vaccine Spikevax jumped 44 percent during ...The phone is ringing. Should you answer? If it’s an important call, of course you want to take it. But so many phone calls today are nothing but spam. How do you tell the difference before you -pick up the phone? Here are some tips to help ...And diluted loss per share was $3.62 compared to diluted earnings per share of $5.24 in 2022. We ended Q2 with cash and investments of $14.6 billion compared to $16.4 billion at the end of the ...At Moderna, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. ...According to the issued ratings of 18 analysts in the last year, the consensus rating for Moderna stock is Hold based on the current 3 sell ratings, 9 hold ratings and 6 buy ratings for MRNA. The average twelve-month price prediction for Moderna is $143.02 with a high price target of $231.00 and a low price target of $60.00.Nov 2, 2023 · Calendar Moderna, Inc. Equities MRNA US60770K1079 Market Closed ... Q1 2023 Earnings Release Moderna Stock: Earnings Come In Light. The fourth quarter came up mixed for Moderna. Revenue beat expectations at $5.08 billion, but declined 29.5%. Analysts projected $5.02 billion in sales ... Moderna, Inc. reported Q2 FY 2022 earnings results that far surpassed analyst expectations. Earnings per share (EPS) was positive for the sixth straight …Moderna, Inc. reported Q2 FY 2022 earnings results that far surpassed analyst expectations. Earnings per share (EPS) was positive for the sixth straight …Earnings Per Share: Diluted EPS decreased by 67% to $2.53 in the third quarter of 2022, compared to the same period in 2021. Cash Position: Cash, cash …MRNA | Complete Moderna Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.In Thursday's earnings, Moderna said 25% of its clinical trials participants are 65 or older. Also, 17% had co-morbid risk factors. It said 37% of participants are "from diverse communities."Moderna reported $1.8 billion in revenue, beating estimates, but recorded a massive GAAP earnings-per-share loss. Wall Street analysts lowered price targets for Moderna stock following the ...Nov 2, 2023 · 2023 Commercial Updates COVID - 19: The Company reported $1.8 billion in Spikevax® (COVID-19 vaccine) sales in the third quarter of 2023, which includes $0.9 billion of U.S. sales and $0.8 billion of international sales. This leads to $3.9 billion in vaccine sales for the year through the third quarter. Moderna (MRNA) came out with quarterly earnings of $3.61 per share, missing the Zacks Consensus Estimate of $4.66 per share. This compares to earnings of $11.29 per share a year ago.Moderna Earnings Estimates High, But Sentiment Low. Moderna (MRNA, $342.87) is another healthcare stock that hit a record high in August but has since pulled back. The shares are down about 30% ...Moderna shares fell by more than 16% on Thursday after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.. The company said ...Aug 3, 2023 · And diluted loss per share was $3.62 compared to diluted earnings per share of $5.24 in 2022. We ended Q2 with cash and investments of $14.6 billion compared to $16.4 billion at the end of the ... Moderna MRNA will report third-quarter 2022 results on Nov 3, before market open.In the last reported quarter, the company delivered an earnings surprise of 16.44%. Moderna’s shares have plunged ...Moderna’s upcoming earnings report date is Feb 22, 2024 which is in 84 days. How were Moderna’s earnings last quarter? Moderna released its earnings results on Nov 02, 2023. The company reported -$9.53 earnings per share for the quarter, missing the consensus estimate of -$1.932 by -$7.598.Moderna’s Q3 profit before tax for 9 months ending September 30 is $7.8 billion on $11.2 billion revenue giving a pre-tax profit margin of 70 percent. The company projects full year 2021 sales ...Earnings ESP: Moderna’s Earnings ESP is +5.90% as the Most Accurate Estimate of a loss of $3.61 is lower than the Zacks Consensus Estimate of a loss of $3.84. You can uncover the best stocks to ...Moderna Inc. reported lower revenue and earnings in the fourth quarter due to lower demand for its Covid-19 vaccines, while the drugmaker prepares to shift to commercial distribution of the shots.Feb 23, 2023 · Fourth Quarter and Full Year 2022 Financial Results. Revenue: Total revenue for the fourth quarter of 2022 was $5.1 billion, compared to $7.2 billion in the same period in 2021, mainly due to a decrease in sales of the Company's COVID-19 vaccines. Product sales for the fourth quarter of 2022 were $4.9 billion, a decrease of 30% compared to the ... Moderna shares fell by more than 16% on Thursday after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.. The company said ...Aug 5, 2021 · Moderna (MRNA) Financial Results: Analysis . Moderna, Inc. reported Q2 FY 2021 earnings that matched analyst expectations.Earnings per share (EPS) came in positive for the second straight quarter ... Pfizer and Moderna, two of the companies producing updated covid vaccines, previously suggested they would charge $110 to $130 per dose, and plan to offer programs for people who cannot afford the vaccines. ... In a recent Moderna earnings call, company officials indicated they are negotiating contracts with payers but did not give per …Moderna's long-term goal is to reduce its cost structure to 20% to 25% of sales, returning gross margins to 75% to 80%. On the third quarter 2023 earnings call, the CFO said:Moderna (MRNA), the maker of a leading Covid-19 vaccine, is down 37% in January (through January 28). Why such a big decline? ... At 11 times recent earnings (and only six times predicted earnings ...Quarterly Results Financial Summary Table View or download the webcast for Moderna's quarterly financial results press releases for 2021 and 2022.Oct 28, 2022 · Moderna MRNA will report third-quarter 2022 results on Nov 3, before market open.In the last reported quarter, the company delivered an earnings surprise of 16.44%. Moderna’s shares have plunged ... Here’s what Moderna reported compared with Wall Street’s expectations, based on a survey of analysts by Refinitiv: Earnings per share: 19 cents per share vs. a loss of $1.77 per share expected ...Retirement is a major milestone in life, and many people dream of retiring early. If you are considering retiring at the age of 62, you may be wondering how much you can earn during your retirement years.Feb 24, 2023 · Moderna Inc. reported lower revenue and earnings in the fourth quarter due to lower demand for its Covid-19 vaccines, while the drugmaker prepares to shift to commercial distribution of the shots. In releasing its third-quarter earnings, Moderna said it is now expecting to deliver between 700 million and 800 million doses this year, down from its previous …Nov 3, 2022 · Moderna’s third quarter revenue was $3.36 billion, down 32% from the same period in 2021. The company booked net income of $1.04 billion for the quarter, down 68% year over year. Its cash ... Moderna, Inc. (NASDAQ:MRNA) issued its earnings results on Thursday, November, 2nd. The company reported ($1.39) EPS for the quarter, beating the consensus estimate of ($2.01) by $0.62. The business earned $1.83 billion during the quarter, compared to analysts' expectations of $1.37 billion.Aug 5, 2021 · Moderna (MRNA) Financial Results: Analysis . Moderna, Inc. reported Q2 FY 2021 earnings that matched analyst expectations.Earnings per share (EPS) came in positive for the second straight quarter ... By Liz Moyer. Options: Highest Open Interest. Options: Highest Implied VolatilityAug 5, 2021 · The drug maker easily bested Wall Street expectations in the year’s second quarter, according to Moderna’s Q2 2021 earnings report released Thursday, with $4.4 billion in total revenues over ... Moderna revenue for the twelve months ending June 30, 2023 was $10.654B, a 53.67% decline year-over-year. Moderna annual revenue for 2022 was $19.263B, a 4.29% increase from 2021. Moderna annual revenue for 2021 was $18.471B, a 2200.25% increase from 2020. Moderna annual revenue for 2020 was $0.803B, a 1238.33% increase from 2019.Moderna sold $5.9 billion of its Covid vaccine in the first quarter, blowing out revenue and profit expectations. The biotech company’s shares soared by more than 7% …Moderna missed earning last week and reduced the guidance for 2021; this reduction was not driven by lack of demand, it was driven by delays in manufacturing. BNTX-PFE jumped in and took over the demand Moderna failed to serve. The current drop is still an overreaction of the market to the Pfizer anti-viral which cause a lot of Stop/Loss drops ...Moderna has started a new phase 3 study with an updated formulation that is intended to increase efficacy against influenza B, as the original version failed to show non-inferiority to current flu ...Feb 23, 2023 · Moderna reported quarterly earnings of $3.61 per share, a 68% decrease from the same period in 2021 when it booked $11.29 per share. The figure fell short of the $4.68 a share Wall Street expected. Agreement is the extent to which all earnings estimates are being revised in the same direction. The greater the percentage of estimates moving higher, the better the score will be for this component.Moderna will announce its Q1'23 earnings tomorrow, Thursday, May 4th. The company is reliant on COVID vaccine revenues only in 2023 - no other new products will be launched this year. Moderna ...Moderna says 70% of sales in the second half of 2023 will take place in the fourth quarter. The prediction is based on $4 billion from existing agreements and $2 billion to $4 billion in ...An Atlas Venture-backed startup developing gene therapies is laying off nearly half of its workforce. Generation Bio Co. (Nasdaq: GBIO) said Wednesday that it …Moderna, Inc. ( MRNA) reported Q1 FY 2022 earnings that far surpassed analyst expectations. Earnings per share (EPS) came in positive for the fifth straight …Net (Loss) Income: Net loss was $ (1.4) billion for the second quarter of 2023, compared to net income of $2.2 billion for the second quarter of 2022. (Loss) Earnings Per Share: Diluted loss per share was $ (3.62) for the second quarter of 2023, compared to diluted earnings per share of $5.24 for the second quarter of 2022.Earnings ESP: Moderna’s Earnings ESP is +5.90% as the Most Accurate Estimate of a loss of $3.61 is lower than the Zacks Consensus Estimate of a loss of $3.84. You can uncover the best stocks to ...Yes, Moderna's earnings are set to decline from earlier pandemic levels. But the pandemic was an unusual situation, making it a difficult and unfair point of comparison. A dirt cheap valuationModerna Inc. research and ratings by Barron's. View MRNA revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.Fourth Quarter and Full Year 2022 Financial Results. Revenue: Total revenue for the fourth quarter of 2022 was $5.1 billion, compared to $7.2 billion in the same period in 2021, mainly due to a decrease in sales of the Company's COVID-19 vaccines. Product sales for the fourth quarter of 2022 were $4.9 billion, a decrease of 30% compared to the ...Moderna MRNA will report second-quarter 2022 results on Aug 3, before the market closes. In the last reported quarter, the company delivered an earnings surprise of 65.54%. Moderna’s shares have ...Moderna reported Q1 FY 2022 earnings that crushed analysts’ expectations. The company reported its fifth straight quarter of positive EPS after a long string of losses per share.Net Income: Net income was $79 million in the first quarter of 2023, compared to net income of $3.7 billion for the first quarter of 2022. Earnings Per Share: Diluted …For the next fiscal year, the consensus earnings estimate of -$3.62 indicates a change of -24.5% from what Moderna is expected to report a year ago.Investor Relations Overview. Deliver on the promise of mRNA science to create a new generation of transformative medicines for patients. Overview of Moderna news, events & presentations, latest quarterly results, and Moderna's pipeline development programs. The internet has revolutionized the way we learn, and now it’s easier than ever to earn a degree from an online school. But with so many options, it can be hard to know where to start. Here are some frequently asked questions about earning ...Earnings Whispers is the only provider of real, professional whisper numbers for professional traders and investors - the most reliable earnings expectation availabe - based on superior fundamental research that is combined with investor sentiment data, quantitative studies, and technical analysis to create a valuable indicator for favorable trading and …Moderna will be looking to display strength as it nears its next earnings release. In that report, analysts expect Moderna to post earnings of -$3.97 per share. This would mark a year-over-year ...Moderna, Inc. (NASDAQ:NASDAQ:MRNA) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ETCompany ParticipantsLavina Talukdar - Head of Investor...Moderna will announce its Q1'23 earnings tomorrow, Thursday, May 4th. The company is reliant on COVID vaccine revenues only in 2023 - no other new products will be launched this year. Moderna ...Moderna Stock: Earnings Come In Light. The fourth quarter came up mixed for Moderna. Revenue beat expectations at $5.08 billion, but declined 29.5%. Analysts projected $5.02 billion in sales ... Moderna, Inc. ( MRNA) reported Q1 FY 2022 earnings that far surpassed analyst expectations. Earnings per share (EPS) came in positive for the fifth straight …With pre-orders of the Pfizer, Moderna, and AstraZeneca vaccines, some countries could vaccinate their entire population. At this point in the Covid-19 pandemic, three vaccine research and development groups—BioNTech and Pfizer; Moderna; an...Earnings ESP: Moderna’s Earnings ESP is +6.83% as the Most Accurate Estimate of loss of $1.65 is lower than the Zacks Consensus Estimate of a loss of $1.77. You can uncover the best stocks to ...Merck & Co. Viralytics Moderna Earnings. Merck & Co. is bidding adieu to the oncolytic virus acquired from its 2018 purchase of Viralytics, with the pipeline change disclosed weeks after the Big ...Moderna (MRNA) Q4 2022 Earnings Call Transcript. MRNA earnings call for the period ending December 31, 2022. Motley Fool Transcribing | Feb 23, 2023 View More MRNA Earnings TranscriptsIn Moderna's previous earnings report, the company forecast $20 billion in coronavirus vaccine sales for 2021. This is according to advance purchase agreements with various governments -- and the ...Moderna (MRNA) will release its next earnings report on Feb 22, 2024. In the last quarter Moderna reported -$1.932 EPS in relation to -$9.53 expected by the market.Moderna Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ... Per-Share Earnings, Actuals & Estimates Moderna Inc. Quarterly; Annual; Actual Analyst Range Consensus. 10 ...Moderna earnings

May 4, 2022 · Moderna CEO Stephane Bancel on earnings: We expect second half of 2022 to be stronger. Moderna sold $5.9 billion of its Covid vaccine in the first quarter, blowing out revenue and profit ... . Moderna earnings

moderna earnings

Moderna MRNA reported third-quarter results that were weaker than we had anticipated, largely due to significant manufacturing resizing expenses to allow the firm to adjust to the endemic phase of ...2023 Commercial Updates COVID - 19: The Company reported $1.8 billion in Spikevax® (COVID-19 vaccine) sales in the third quarter of 2023, which includes $0.9 billion of U.S. sales and $0.8 billion of international sales. This leads to $3.9 billion in vaccine sales for the year through the third quarter.Quarterly Results Financial Summary Table View or download the webcast for Moderna's quarterly financial results press releases for 2021 and 2022.Moderna Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ... Per-Share Earnings, Actuals & Estimates Moderna Inc. Quarterly; Annual; Actual Analyst Range Consensus. 10 ...ALNY. Alnylam Pharmaceuticals Inc. 164.01. UNCH. UNCH. Get Moderna Inc (MRNA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Net (Loss) Income: Net loss was $ (1.4) billion for the second quarter of 2023, compared to net income of $2.2 billion for the second quarter of 2022. (Loss) Earnings Per Share: Diluted loss per share was $ (3.62) for the second quarter of 2023, compared to diluted earnings per share of $5.24 for the second quarter of 2022.Moderna, Inc. (NASDAQ:NASDAQ:MRNA) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ETCompany ParticipantsLavina Talukdar – Head-Investor...See Moderna, Inc. (MRNA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.According to the issued ratings of 18 analysts in the last year, the consensus rating for Moderna stock is Hold based on the current 3 sell ratings, 9 hold ratings and 6 buy ratings for MRNA. The average twelve-month price prediction for Moderna is $143.02 with a high price target of $231.00 and a low price target of $60.00.s29.q4cdn.comNet (Loss) Income: Net loss was $ (1.4) billion for the second quarter of 2023, compared to net income of $2.2 billion for the second quarter of 2022. (Loss) Earnings Per Share: Diluted loss per share was $ (3.62) for the second quarter of 2023, compared to diluted earnings per share of $5.24 for the second quarter of 2022.Moderna will announce its Q1'23 earnings tomorrow, Thursday, May 4th. The company is reliant on COVID vaccine revenues only in 2023 - no other new products will be launched this year. Moderna ...In today’s digital age, more and more people are turning to online jobs as a way to earn a living. Whether you’re looking for a side hustle or a full-time career, the flexibility and convenience of working from home can be incredibly appeal...Moderna slumped to a far bigger quarterly loss than expected and delivered a disappointing sales forecast, sending shares in the Covid-19 vaccine maker down as much as 18 per cent.The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...Moderna on Thursday said its 2023 sales would only hit the low end of its $6 billion to $8 billion forecast, reflecting weaker demand for COVID-19 vaccines, and its shares slumped 8%.Pfizer and Moderna, two of the companies producing updated COVID vaccines, previously suggested they would charge $110 to $130 per dose, and plan to offer programs for people who cannot afford the vaccines. ... In a recent Moderna earnings call, company officials indicated they are negotiating contracts with payers but did not give per …The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...Earnings ESP: Moderna’s Earnings ESP is +5.90% as the Most Accurate Estimate of a loss of $3.61 is lower than the Zacks Consensus Estimate of a loss of $3.84. You can uncover the best stocks to ...See Moderna, Inc. (MRNA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.Moderna beat Wall Street's quarterly earnings and revenue expectations. The Boston biotech company generated $4.7 billion in sales for the quarter, a 9% increase over the same period last year.The ongoing Covid-19 pandemic propelled pharmaceutical company Pfizer’s earnings to a record $100 billion last year, almost $57 billion of which was driven by its vaccine and antiviral pill ...Moderna (MRNA) reports third-quarter earnings before the market opens on Nov. 3. Profit is expected to decline by two-thirds as revenue drops for the first time in 11 quarters.Nov 1, 2021 · Moderna, Inc. MRNA will report third-quarter 2021 results on Nov 4, before market open. In the last reported quarter, the company delivered an earnings surprise of 7.49%. Moderna’s share price ... Moderna posted net income of $79 million, or 19 cents per share, for the quarter. That's compared with $3.66 billion in net income, or $8.58 per share, reported …Moderna MRNA reported third-quarter results that were weaker than we had anticipated, largely due to significant manufacturing resizing expenses to allow the firm to adjust to the endemic phase of ...Here’s what Moderna reported compared with Wall Street’s expectations, based on a survey of analysts by Refinitiv: Earnings per share: 19 cents per share vs. a loss of $1.77 per share expected ...Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. -863.75M. -301.46%. Get the latest Moderna Inc (MRNA) real-time quote, historical ... Aug 3, 2023 · Moderna posted a net loss of $1.38 billion, or $3.62 per share, for the quarter. That compares with $2.20 billion in net income, or $5.24 per share, reported during the same quarter last year. Moderna, Inc. MRNA reported earnings of $5.24 per share for the second quarter of 2022, beating the Zacks Consensus Estimate of $4.45. The company had reported earnings of $6.46 per share in the ...For the next fiscal year, the consensus earnings estimate of -$3.62 indicates a change of -24.5% from what Moderna is expected to report a year ago.Apr 29, 2023 · The company decided his pay wasn’t good enough. The Cambridge, Mass.-based biotech, known for its lifesaving coronavirus vaccine, raised his salary last year by 50 percent to $1.5 million and ... Investor Relations Overview. Deliver on the promise of mRNA science to create a new generation of transformative medicines for patients. Overview of Moderna news, events & presentations, latest quarterly results, and Moderna's pipeline development programs. Nov 2, 2023 · 2023 Commercial Updates COVID - 19: The Company reported $1.8 billion in Spikevax® (COVID-19 vaccine) sales in the third quarter of 2023, which includes $0.9 billion of U.S. sales and $0.8 billion of international sales. This leads to $3.9 billion in vaccine sales for the year through the third quarter. Earnings ESP: Moderna’s Earnings ESP is +5.90% as the Most Accurate Estimate of a loss of $3.61 is lower than the Zacks Consensus Estimate of a loss of $3.84. You can uncover the best stocks to ...Earnings Date. Feb 21, 2024 - Feb 26, 2024. Forward Dividend & Yield. N/A (N/A) Ex-Dividend Date. N/A. 1y Target Est. 122.40. Fair Value is the appropriate price for the shares of a company, based ...Moderna stock fell 4.4% Friday to an eight-month low of $160, pushing shares down more than 20% over the past week amid growing research suggesting Moderna’s Covid-19 booster, while very ...Oct 28, 2022 · Moderna MRNA will report third-quarter 2022 results on Nov 3, before market open. In the last reported quarter, the company delivered an earnings surprise of 16.44%. Moderna’s shares have ... 2023 Commercial Updates COVID - 19: The Company reported $1.8 billion in Spikevax® (COVID-19 vaccine) sales in the third quarter of 2023, which includes $0.9 billion of U.S. sales and $0.8 billion of international sales. This leads to $3.9 billion in vaccine sales for the year through the third quarter.s29.q4cdn.comFeb 23, 2023 · Moderna reported quarterly earnings of $3.61 per share, a 68% decrease from the same period in 2021 when it booked $11.29 per share. The figure fell short of the $4.68 a share Wall Street expected. Moderna beat Wall Street's quarterly earnings and revenue expectations. The Boston biotech company generated $4.7 billion in sales for the quarter, a 9% increase over the same period last year.Moderna, Inc. 70.21. +0.16. +0.23%. Moderna, Inc. (NASDAQ:MRNA) Q4 2022 Earnings Call Transcript February 23, 2023 Operator: Good morning. My name is Kevin and welcome to Moderna’s Fourth ...Moderna Earnings Estimates High, But Sentiment Low. Moderna (MRNA, $342.87) is another healthcare stock that hit a record high in August but has since pulled back. The shares are down about 30% ...Moderna, Inc. (NASDAQ:NASDAQ:MRNA) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ETCompany ParticipantsLavina Talukdar - Head of Investor...Moderna revenue for the twelve months ending June 30, 2023 was $10.654B, a 53.67% decline year-over-year. Moderna annual revenue for 2022 was $19.263B, a 4.29% increase from 2021. Moderna annual revenue for 2021 was $18.471B, a 2200.25% increase from 2020. Moderna annual revenue for 2020 was $0.803B, a 1238.33% increase from 2019.Moderna on Thursday said its 2023 sales would only hit the low end of its $6 billion to $8 billion forecast, reflecting weaker demand for COVID-19 vaccines, and its shares slumped 8%.Looking at Moderna, earnings are forecasted to decline -24% this year to $21.48 per share after an excellent FY21. Fiscal 2023 earnings are projected to drop another -78% to $4.58 a share as MRNA ...Moderna stock currently trades at a mere 12x 2021 consensus earnings. The conservative multiple is largely due to the fact that investors expect sales of the Covid vaccine – Moderna’s only .... Low cost index funds